Literature DB >> 29031603

Xanthurenic Acid Formation from 3-Hydroxykynurenine in the Mammalian Brain: Neurochemical Characterization and Physiological Effects.

K V Sathyasaikumar1, M Tararina1, H-Q Wu1, S A Neale2, F Weisz3, T E Salt2, R Schwarcz4.   

Abstract

Xanthurenic acid (XA), formed from 3-hydroxykynurenine (3-HK) in the kynurenine pathway of tryptophan degradation, may modulate glutamatergic neurotransmission by inhibiting the vesicular glutamate transporter and/or activating Group II metabotropic glutamate receptors. Here we examined the molecular and cellular mechanisms by which 3-HK controls the neosynthesis of XA in rat, mouse and human brain, and compared the physiological actions of 3-HK and XA in the rat brain. In tissue homogenates, XA formation from 3-HK was observed in all three species and traced to a major role of kynurenine aminotransferase II (KAT II). Transamination of 3-HK to XA was also demonstrated using human recombinant KAT II. Neosynthesis of XA was significantly increased in the quinolinate-lesioned rat striatum, indicating a non-neuronal localization of the process. Studies using rat cortical slices revealed that newly produced XA is rapidly released into the extracellular compartment, and that XA biosynthesis can be manipulated experimentally in the same way as the production of kynurenic acid from kynurenine (omission of Na+ or glucose, depolarizing conditions, or addition of 2-oxoacids). The synthesis of XA from 3-HK was confirmed in vivo by striatal microdialysis. In slices from the rat hippocampus, both 3-HK and XA reduced the slopes of dentate gyrus field EPSPs. The effect of 3-HK was reduced in the presence of the KAT inhibitor aminooxyacetic acid. Finally, both 3-HK and XA reduced the power of gamma-oscillatory activity recorded from the hippocampal CA3 region. Endogenous XA, newly formed from 3-HK, may therefore play a physiological role in attentional and cognitive processes.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  attention; cognition; gamma oscillations; glia; kynurenine aminotransferases

Mesh:

Substances:

Year:  2017        PMID: 29031603      PMCID: PMC5819007          DOI: 10.1016/j.neuroscience.2017.10.006

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  68 in total

Review 1.  Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?

Authors:  Meng-Lin Li; Xi-Quan Hu; Feng Li; Wen-Jun Gao
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-02-24       Impact factor: 5.067

Review 2.  Endogenous kynurenines as targets for drug discovery and development.

Authors:  Trevor W Stone; L Gail Darlington
Journal:  Nat Rev Drug Discov       Date:  2002-08       Impact factor: 84.694

3.  pH dependence, substrate specificity and inhibition of human kynurenine aminotransferase I.

Authors:  Qian Han; Junsuo Li; Jianyong Li
Journal:  Eur J Biochem       Date:  2004-12

4.  Biochemical and phenotypic abnormalities in kynurenine aminotransferase II-deficient mice.

Authors:  Ping Yu; Nicholas A Di Prospero; Michael T Sapko; Tao Cai; Amy Chen; Miguel Melendez-Ferro; Fu Du; William O Whetsell; Paolo Guidetti; Robert Schwarcz; Danilo A Tagle
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

Review 5.  An expanding range of targets for kynurenine metabolites of tryptophan.

Authors:  Trevor W Stone; Nicholas Stoy; L Gail Darlington
Journal:  Trends Pharmacol Sci       Date:  2012-11-01       Impact factor: 14.819

6.  Xanthurenic acid distribution, transport, accumulation and release in the rat brain.

Authors:  Serge Gobaille; Véronique Kemmel; Daniel Brumaru; Christophe Dugave; Dominique Aunis; Michel Maitre
Journal:  J Neurochem       Date:  2008-01-07       Impact factor: 5.372

7.  Zonisamide regulates basal ganglia transmission via astroglial kynurenine pathway.

Authors:  Kouji Fukuyama; Shunske Tanahashi; Masamitsu Hoshikawa; Rika Shinagawa; Motohiro Okada
Journal:  Neuropharmacology       Date:  2013-08-22       Impact factor: 5.250

Review 8.  Neuronal oscillations: A physiological correlate for targeting mitochondrial dysfunction in neurodegenerative diseases?

Authors:  Felix Chan; Nichola Z Lax; Ceri H Davies; Douglass M Turnbull; Mark O Cunningham
Journal:  Neuropharmacology       Date:  2015-10-28       Impact factor: 5.250

9.  The antioxidant role of xanthurenic acid in the Aedes aegypti midgut during digestion of a blood meal.

Authors:  Vitor L A Lima; Felipe Dias; Rodrigo D Nunes; Luiza O Pereira; Tiago S R Santos; Luciana B Chiarini; Tadeu D Ramos; Bernardo J Silva-Mendes; Jonas Perales; Richard H Valente; Pedro L Oliveira
Journal:  PLoS One       Date:  2012-06-11       Impact factor: 3.240

10.  Xanthurenic Acid Activates mGlu2/3 Metabotropic Glutamate Receptors and is a Potential Trait Marker for Schizophrenia.

Authors:  Francesco Fazio; Luana Lionetto; Martina Curto; Luisa Iacovelli; Michele Cavallari; Cristina Zappulla; Martina Ulivieri; Flavia Napoletano; Matilde Capi; Valentina Corigliano; Sergio Scaccianoce; Alessandra Caruso; Jessica Miele; Antonio De Fusco; Luisa Di Menna; Anna Comparelli; Antonella De Carolis; Roberto Gradini; Robert Nisticò; Antonio De Blasi; Paolo Girardi; Valeria Bruno; Giuseppe Battaglia; Ferdinando Nicoletti; Maurizio Simmaco
Journal:  Sci Rep       Date:  2015-12-08       Impact factor: 4.379

View more
  6 in total

1.  Receptor variants and the development of centrally acting medications
.

Authors:  Stuart A Neale; Kumiko Kambara; Thomas E Salt; Daniel Bertrand
Journal:  Dialogues Clin Neurosci       Date:  2019       Impact factor: 5.986

2.  Combined metabolome and transcriptome analysis reveals key components of complete desiccation tolerance in an anhydrobiotic insect.

Authors:  Alina Ryabova; Richard Cornette; Alexander Cherkasov; Masahiko Watanabe; Takashi Okuda; Elena Shagimardanova; Takahiro Kikawada; Oleg Gusev
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-28       Impact factor: 11.205

3.  Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study.

Authors:  Lieke Bakker; Inez H G B Ramakers; Martin P J van Boxtel; Miranda T Schram; Coen D A Stehouwer; Carla J H van der Kallen; Pieter C Dagnelie; Marleen M J van Greevenbroek; Anke Wesselius; Øivind Midttun; Per M Ueland; Frans R J Verhey; Simone J P M Eussen; Sebastian Köhler
Journal:  Diabetologia       Date:  2021-08-19       Impact factor: 10.122

Review 4.  Hypoxia and the Kynurenine Pathway: Implications and Therapeutic Prospects in Alzheimer's Disease.

Authors:  Oluyomi Stephen Adeyemi; Oluwakemi Josephine Awakan; Lawrence Boluwatife Afolabi; Damilare Emmanuel Rotimi; Elizabeth Oluwayemi; Chiagoziem A Otuechere; Omodele Ibraheem; Tobiloba Chritiana Elebiyo; Omokolade Alejolowo; Afolake T Arowolo
Journal:  Oxid Med Cell Longev       Date:  2021-11-10       Impact factor: 6.543

5.  Cellular Localization of Kynurenine 3-Monooxygenase in the Brain: Challenging the Dogma.

Authors:  Korrapati V Sathyasaikumar; Verónica Pérez de la Cruz; Benjamín Pineda; Gustavo Ignacio Vázquez Cervantes; Daniela Ramírez Ortega; David W Donley; Paul L Severson; Brian L West; Flaviano Giorgini; Jonathan H Fox; Robert Schwarcz
Journal:  Antioxidants (Basel)       Date:  2022-02-04

6.  Biochemical and structural analysis of a cytosolic sulfotransferase of the malaria vector Anopheles gambiae overexpressed in the reproductive tissues.

Authors:  Arianna Esposito Verza; Riccardo Miggiano; Fabrizio Lombardo; Carmine Fiorillo; Bruno Arcà; Beatrice Purghé; Erika Del Grosso; Ubaldina Galli; Menico Rizzi; Franca Rossi
Journal:  Curr Res Struct Biol       Date:  2022-07-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.